

# Subject Index

- Access, to health care
  - social support and, in chronic disease, 336–337
- Acetate hemodiafiltration, 236
- Adaptation
  - outcome-driven nephrology social work, value of, 409–414
- Adherence profiling
  - improving cyclo prescriptions in peritoneal dialysis through, 266–267
- Advance-care planning
  - in ESRD. communicating with patients and families, 407–408
- Advanced CKD. *See* Chronic kidney disease, advanced.
- Alternative dialysis regimens, 227–316
  - editorial, 227–228
  - guest editorial, 229–230
  - hemodialysis, 231–262, *e1*, *e10*, *e17*
    - drug dosing considerations in, *e17*
    - dry weight, sine qua non of adequate dialysis, *e10*
    - future of renal replacement therapy, 249–255
    - hemodiafiltration, history, technology, and clinical results of, 231–243
    - home, ultrapure dialysate for, 256–262
    - increased frequency of, *e1*
    - thrice-weekly in-center nocturnal program, 244–248
  - peritoneal dialysis, 263–289, *e27*, *e35*
    - assisted, 279–283
    - early start, *e27*
    - glucotoxicity in, solutions for, 269–278
    - home therapies, resurgence of, 284–289
    - improving cyclo prescriptions through informatic profiling, 263–268
    - quotidian hemodialysis and inflammation associated with CKD, *e35*
- Amyloidosis
  - dialysis-related, with hemodiafiltration, 241
- Anemia
  - in advanced CKD, stabilization of glomerular filtration rate in, 105–112
  - in pregnant hemodialysis patients, 149–150
  - management during pregnancy in kidney transplant recipients, 163–164
  - with hemodiafiltration, 241
- Anthropometric assessment
  - in children with CKD, 219–220
- Antihypertensive drugs
  - use during pregnancy, 191–198
- Anxiety
  - prevalence in ESRD patients, 85–87
- Arterial complications
  - with vascular calcification in CKD, 41
- Arterial disease, peripheral
  - cardiovascular risk factors for, in incident-dialysis patients, 304–313
- Assessment
  - of health-related quality of life in CKD patients, 345–352
  - psychosocial, of patients on chronic peritoneal dialysis, 353–357
- Assisted peritoneal dialysis, 279–283
  - clinical outcomes, 281–282
- Assisted peritoneal dialysis, 279–283 (*Continued*)
  - initiation of, 280–281
  - suitable candidates for, 280
  - training of PD assistants, 281
- Assisted reproductive technologies
  - ethical issues in pregnancy in CKD, 210
- Azathioprine
  - use during pregnancy in transplant recipients, 160
- Bioartificial kidney
  - in future of renal replacement therapy, 254
- Biomarkers
  - in diagnosis of bone-mineral disorder in patients with CKD, 30
- Biopsies
  - of bone, in patients with CKD, 28–30
- Blood pressure
  - in preeclampsia, 185
  - See also* Hypertension and Preeclampsia.
- Body composition
  - nutrition assessment and hormonal influences on, in children with CKD, 215–223
- Bone
  - abnormalities of in CKD, 6
  - See also* Mineral-bone disorder.
- Bone biopsies
  - in patients with CKD, 28–30
- Bone disease
  - coexistence of mineral-bone disorder with other causes of, 10
- Bone health
  - in CKD–mineral and bone disease, 27–36
  - diagnosis and screening, 27–32
  - biomarkers, 30
  - bone biopsies, 27–30
  - imaging techniques, 30–31
  - metabolic changes, 32–33
  - morphologic presentations, 33–34
- Bone metabolism
  - regulation of, in bone-mineral disorder in patients with CKD, 31–32
- Bone morphogenetic protein (BMP)
  - role of BMP-2/Msx2/Wnt pathway in vascular calcification, 57
  - role of BMP-7 in vascular calcification, 59
- Breast-feeding
  - by kidney transplant recipients, 164–165
  - in women on antihypertensive drugs, 188–189
- C-reactive protein
  - cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients, 304–313
- Calcification, vascular. *See* Vascular calcification.
- Calcimimetics
  - for elevated parathyroid hormone in CKD–bone-mineral disorder, 51
- Calcineurin inhibitors
  - use during pregnancy in transplant recipients, 160
- Calcium
  - in CKD, recommended intake and serum targets, 75–78

- Calcium (*Continued*)  
 role of calcium/vitamin D/parathyroid hormone/fibroblast growth factor 23 axis in vascular calcification, 56–57  
 serum concentration in CKD, clinical outcome related to, 15–16
- Calcium-phosphorus product  
 in CKD, clinical outcome related to, 16–17
- Cardiovascular disease  
 testing for, Medicare reimbursement for preventive services (Special Article), 79–80
- Cardiovascular risk factors  
 for peripheral arterial disease, in incident-dialysis patients, 304–313
- Child Health and Illness Profile-Adolescent Edition, 366
- Children's Health Questionnaire, 366–367
- Children. *See* Pediatrics.
- Chronic hypertension. *See* Hypertension.
- Chronic kidney disease (CKD)  
 advanced, stabilization of glomerular filtration rate in, 2-year follow-up of, 105–112  
 alternative dialysis regimens, 227–316  
 editorial, 227–228  
 guest editorial, 229–230  
 hemodialysis, 231–262, *e1*, *e10*, *e17*  
 drug dosing considerations in, *e17*  
 dry weight, sine qua non of adequate dialysis, *e10*  
 future of renal replacement therapy, 249–255  
 hemodiafiltration, history, technology, and clinical results of, 231–243  
 home, ultrapure dialysate for, 256–262  
 increased frequency of, *e1*  
 thrice-weekly in-center nocturnal program, 244–248  
 peritoneal dialysis, 263–289, *e27*, *e35*  
 assisted, 279–283  
 early start, *e27*  
 glucotoxicity in, solutions for, 269–278  
 home therapies, resurgence of, 284–289  
 improvingycler prescriptions through informatic profiling, 263–268  
 quotidian hemodialysis and inflammation associated with CKD, *e35*
- Medicare reimbursement for preventive services (Special Article), 79–81
- Mental health and quality of life in, 315–408  
 after kidney transplantation, 370–378  
 assessment of health-related quality of life in, 345–352  
 depression in ESRD patients, 328–334  
 dialysis discontinuation, 379–401  
 editorial, 315  
 health-related quality of life for children with, 364–369  
 in women with ESRD, 358–364  
 palliative care in ESRD, 402–408  
 psychosocial assessment of chronic peritoneal dialysis patients, 353–357  
 psychosocial factors (guest editorial), 316–318
- Chronic kidney disease (CKD) (*Continued*)  
 social support and, 335–344  
 symptoms and their correlates, 319–327  
 common distressing, and their treatment, 321–324  
 in peritoneal dialysis and pre-ESRD patients, 324–323  
 overall burden, severity, and importance of, 320–321  
 mineral metabolism and mortality in patients with, 13–21  
 clinical outcomes related to  
 calcium-phosphorus product, 16–17  
 parathyroid hormone, 17–19  
 serum calcium concentration, 15–16  
 serum phosphorus concentration, 13–15  
 mechanism of link between, 19–20  
 mineral-bone disorder (CKD-MBD) in, 1–66  
 bone health in, 27–36  
 diagnosis and screening, 27–32  
 metabolic changes, 32–33  
 morphologic presentations, 33–34  
 editorial, 1  
 guest editorial, 2  
 management of, 44–53  
 parathyroid hormone control, 47–51  
 phosphorus control, 45–47  
 mechanisms of vascular calcification, 54–66  
 new paradigm, 3–12  
 abnormalities of bone in, 6  
 clinical manifestations of disturbances in, 4–6  
 coexistence with other causes of bone and vascular disease, 10  
 establishment of, 8  
 renal osteodystrophy, 8–9  
 vascular calcification in, 6–8  
 clinical assessment of, 37–43  
 nutrition assessment and hormonal influences on body composition in children with, 215–223  
 pregnancy and, 113–214  
 antihypertensive and immunosuppressive medications during, 191–198  
 contraceptive counseling for women with, 126–131  
 editorial, 113–114  
 ethical considerations in, 206–211  
 guest editorial, 115  
 historical perspective, 116–118  
 hypertension in, 178–190  
 in kidney transplant recipients  
 contraceptive counseling for, 126–131  
 medical management of, 156–167  
 obstetric considerations in, 168–177  
 management of chronic dialysis in, 146–155  
 maternal and fetal outcomes, 132–145  
 nutritional management of, 212–214  
 outcome of infants born to women with, 199–205  
 sexual function in CKD, 119–125  
 vitamin D in patients with, 22–26

- Chronic kidney disease (CKD) (*Continued*)  
*See also* End-stage renal disease.
- Chronic renal insufficiency  
 nutrition assessment and hormonal influences  
 on, in children with, 215–223
- CKD. *See* Chronic kidney disease.
- Communication  
 with ESRD patients and families, 403–406  
 advance-care planning, 405–406  
 end-of-life discussions, 404–405  
 prognosis, 403–404
- Compliance  
 in women with ESRD, 360  
 social support and, in chronic disease, 338–339
- Computed tomography  
 in assessment of vascular calcification in CKD,  
 39–41
- Conception  
 in women with ESRD, 359–360
- Congenital anomalies  
 in infants born to women with CKD, 202
- Contraception  
 counseling on, in women with CKD or after  
 kidney transplantation, 129–130
- Corticosteroids  
 use during pregnancy in transplant recipients,  
 159–160
- Counseling  
 about pregnancy in transplant recipients, 156–  
 157, 168–169  
 ethical issues in pregnancy in CKD, 206–207  
 on pregnancy and contraception in women with  
 CKD, 126–131
- Cycler therapy  
 improvement in peritoneal dialysis prescriptions  
 through informatic profiling, 263–268
- Cyclosporine  
 use during pregnancy in transplant recipients,  
 160
- Cytokines  
 nutrition assessment and hormonal influences  
 on, in children with CKD, 215–223
- Cytomegalovirus  
 infections during pregnancy in kidney transplant  
 recipients, 173
- Daily dialysis  
 frequent hemodialysis in children, 297–303  
 should Medicare ESRD program pay for, ethical  
 analysis of, 290–296
- Death, patient  
 decision to discontinue dialysis, 379–401
- Depression  
 in ESRD patients, 328–334  
 outcome and, 329–330  
 symptom or diagnosis, 329  
 treatment, 330  
 outcome-driven nephrology social work, value  
 of, 409–414  
 prevalence in ESRD patients, 85–87  
 psychosocial assessment of patients on chronic  
 peritoneal dialysis, 353–357
- Depression (*Continued*)  
 social support and, in chronic disease, 337–338
- Developmental outcomes  
 of infants born to women with CKD, 203
- Diabetes  
 testing for, Medicare reimbursement for preven-  
 tive services (Special Article), 79–80
- Diabetic nephropathy  
 pregnancy outcomes in, 140–141
- Dialysate  
 ultrapure, for home hemodialysis, 256–262
- Dialysis  
 alternative regimens, 227–316  
 editorial, 227–228  
 guest editorial, 229–230  
 hemodialysis, 231–262, *e1*, *e10*, *e17*  
 drug dosing considerations in, *e17*  
 dry weight, sine qua non of adequate dialy-  
 sis, *e10*  
 future of renal replacement therapy, 249–  
 255  
 hemodiafiltration, history, technology, and  
 clinical results of, 231–243  
 home, ultrapure dialysate for, 256–262  
 increased frequency of, *e1*  
 thrice-weekly in-center nocturnal program,  
 244–248  
 peritoneal dialysis, 263–289, *e27*, *e35*  
 assisted, 279–283  
 early start, *e27*  
 glucotoxicity in, solutions for, 269–278  
 home therapies, resurgence of, 284–289  
 improving cycler prescriptions through in-  
 formatic profiling, 263–268  
 quotidian hemodialysis and inflammation  
 associated with CKD, *e35*  
 assessment of health-related quality of life in  
 patients on, 345–352  
 cost of, burden for uninsured patients, 69  
 daily, should Medicare ESRD program pay for,  
 ethical analysis of, 290–296  
 discontinuation of, 379–401  
 current evidence and practice, 379–396  
 future clinical and research directions, 396–399
- hemodialysis  
 custom-made Raster method for fistula and  
 graft (abstract), 224  
 ESRD patients on, in hurricane-prone areas,  
 102–103  
 frequent, in children, 297–303  
 daily intensive hemodiafiltration, 298  
 dose monitoring, 302  
 dose prescription, 301–302  
 nocturnal, 298–300  
 potential deficiency syndromes, 301  
 with NxStage system, 301  
 injectable vitamin D and survival on, 23–24
- incident-dialysis patients, cardiovascular risk  
 factors for peripheral arterial disease in,  
 304–313

- Dialysis (*Continued*)
- peritoneal dialysis
    - impact of focused techniques on peritonitis rates (abstract), 224
    - increased utilization for ESRD patients in hurricane-prone areas, 103–104
    - psychosocial assessment of patients on chronic, 353–357
    - symptoms and quality of life in patients on, 324–325
  - pregnant patients on, 146–155
    - diagnosis of pregnancy in, 147
    - frequency of, 146–147
    - management of, 149–154
      - anemia, 149–150
      - diet, 153–154
      - hemodialysis, 151–152
      - hypertension, 150–151
      - peritoneal dialysis, 152–153
    - outcomes, 147–149
    - symptoms in ESRD patients managed without or discontinuing, 91
- Diet
- management of, in pregnant dialysis patients, 153–154
- Dietary intake
- in children with CKD, 216–218
- Disaster preparedness
- ESRD care in hurricane-prone areas, 100–104
    - development of central electronic medial record for, 104
    - event summary, 100–102
    - should dialysis units rebuild, 102
    - should ESRD patients in hemodialysis reside in, 102–103
    - should ESRD patients undergo evaluation for hemodialysis or transplantation, 103
- Echocardiography
- in assessment of vascular calcification in CKD, 39
- Electronic health records
- central system for ESRD patients in disaster-prone areas, 104
- End-of-life care
- in ESRD, 402–408
    - communicating with patients and families, 403–406
      - advance-care planning, 405–406
      - end-of-life discussions, 404–405
      - prognosis, 403–404
    - dialysis discontinuation, 379–401
    - hospice, 406
- End-of-life discussions
- in ESRD. communicating with patients and families, 406–407
- End-stage renal disease (ESRD)
- cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients, 304–313
  - in hurricane-prone areas, utilization of peritoneal dialysis in, 100–104
  - prevalence of symptoms in, 82–99
- End-stage renal disease (ESRD) (*Continued*)
- psychosocial and quality of life issues in women with, 358–361
  - uninsured patients with, 67–74
- Energy needs
- in pregnancy in CKD, 212–213
- Epidemiology
- maternal and fetal outcomes of pregnancy with CKD, 132–145
  - three early intervention programs, evaluation of (abstract), 224
- Errata, 112, 313
- Erythropoietin
- and sexual function in CKD, 121
- ESRD. *See* End-stage renal disease.
- Ethics
- issues of pregnancy in chronic kidney disease, 206–211
    - assisted reproductive technologies, 210
    - fetus as a patient, 208
    - informed consent and counseling, 206–207
    - resource allocation, 208–209
    - responsibilities for increased research and public debate, 210–211
    - rights, 208
    - shortened life expectancy, 207–208
  - should Medicare ESRD program pay for daily dialysis, 290–296
- Fertility
- in women with ESRD, 359–360
- Fetuin A
- role in vascular calcification in CKD, 58–59
- Fetus
- as a patient, as ethical issue in pregnancy in CKD, 208
  - outcomes of, in pregnancy with CKD, 132–145
- Fibrinogen
- cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients, 304–313
- Fibroblast growth factor 23
- role of calcium/vitamin D/parathyroid hormone/FGF-23 axis in vascular calcification, 56–57
- Flow profiling
- improving cyclers prescriptions in peritoneal dialysis through, 264–266
- Frequent hemodialysis. *See* Hemodialysis.
- Gestational hypertension, 179
- Glomerular filtration rate
- stabilization of, in advanced CKD, 2-year follow-up of, 105–112
- Glucose
- toxicity of, in peritoneal dialysis, 269–278
- Glucose-sparing regimens
- for peritoneal dialysis, 272–278
    - long-dwell “bimodal” solutions, 274–275
    - nonglucose osmotic agents, 274
    - pharmacokinetic abrogation of, 275–276
    - small-molecular weight molecules, 275

- Glucotoxicity, in peritoneal dialysis  
contemporary strategies for glucose sparing, 272–273  
emerging clinical benefits of glucose-sparing regimens, 273  
future solutions for, 274–276  
  long-dwell “bimodal” solutions, 274–275  
  nonglucose osmotic agents, 274  
  pharmacokinetic abrogation of, 275–276  
  small-molecular weight molecules, 275  
pathogenetic mechanisms of excessive glucose exposure, 269–272
- Hard hemodiafiltration, 236
- Health care  
  access to, social support and, in chronic disease, 336–337
- Health consequences  
  for uninsured ESRD patients, 68–69
- Health-related quality of life. *See* Quality of life.
- Hemodiafiltration  
  clinical effects and studies on, 240–242  
  daily intensive, in children, 298  
  history of, 231–232  
  mechanisms of solute removal, 232–236  
  techniques, 236–240  
    acetate-free biofiltration, 236  
    classic, 236  
    double high-flux, 238  
    high-volume (“hard”), 236  
    internal filtration, 236–237  
    middilution, 238  
    online, 236, 239–240  
    paired filtration, 237  
    push-pull, 238–239
- Hemodialysis  
  alternative regimens, 231–262, *e1*, *e10*, *e17*  
  drug dosing considerations in, *e17*  
  dry weight, sine qua non of adequate dialysis, *e10*  
  future of renal replacement therapy, 249–255  
  hemodiafiltration, history, technology, and clinical results of, 231–243  
  home, ultrapure dialysate for, 256–262  
  increased frequency of, *e1*  
  thrice-weekly in-center nocturnal program, 244–248  
  custom-made Raster method for fistula and graft (abstract), 224  
  ESRD patients on, in hurricane-prone areas, 102–103  
  frequent, in children, 297–303  
    daily intensive hemodiafiltration, 298  
    dose monitoring, 302  
    dose prescription, 301–302  
    nocturnal, 298–300  
    potential deficiency syndromes, 301  
    with NxStage system, 301  
  in pregnant patients, 151–152  
  injectable vitamin D and survival on, 23–24
- Hepatitis B and C  
  infections during pregnancy in kidney transplant recipients, 173–174
- Heremans-Schmid glycoprotein,  $\alpha$ 2-  
  role in vascular calcification in CKD, 58–59
- Herpes simplex  
  infections during pregnancy in kidney transplant recipients, 173
- Home dialysis therapies  
  for hemodialysis, ultrapure dialysate for, 256–262  
  resurgence of, 284–389  
    improving outcomes through, 285–286  
    models, modalities, and machines, 287–288  
    patient preference for, 286–287  
    selection of, 285
- Homocysteine  
  cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients, 304–313
- Hormone replacement therapy  
  for sexual dysfunction in CKD, 120–123
- Hospice  
  palliative care in ESRD patients, 406
- Human nephron filter  
  in future of renal replacement therapy, 250–253
- Hurricane-prone areas  
  ESRD care in, utilization of peritoneal dialysis for, 100–104  
  development of central electronic medial record for, 104  
  event summary, 100–102  
  should dialysis units rebuild, 102  
  should ESRD patients in hemodialysis reside in, 102–103  
  should ESRD patients undergo evaluation for hemodialysis or transplantation, 103
- Hypertension  
  in pregnancy, 178–190  
  antihypertensive use during, 191–198  
  chronic, 179–184  
    differential diagnosis, 179–181  
    fetal risks, 181–182  
    general management principles, 182–183  
    maternal risks, 181  
  classification of, 178–179  
  chronic, 178  
  gestational, 179  
  preeclampsia superimposed on chronic, 179  
  preeclampsia-eclampsia, 178–179  
  postpartum counseling and follow-up, 188–190  
  antihypertensives and lactation, 188–190  
  preeclampsia, 184–188  
  clinical features and diagnosis, 184  
  pathophysiology of, 185–186  
  prevention and management, 184–185  
  treatment, 186–188  
  in pregnant hemodialysis patients, 150–151  
  management during pregnancy in kidney transplant recipients, 162–163, 170–172

- Hypogonadism  
 in men with CKD, 122  
 sildenafil citrate, 123  
 testosterone replacement therapy, 122
- Hypotension  
 dialysis, with hemodiafiltration, 240–241
- Illegal immigrants  
 uninsured, with ESRD, 71–72
- Imaging  
 in assessment of vascular calcification in CKD, 37–41  
 in diagnosis of bone-mineral disorder in patients with CKD, 30–31
- Immigrants, illegal  
 uninsured, with ESRD, 71–72
- Immune function  
 social support and, in chronic disease, 340
- Immunosuppressive drugs  
 use during pregnancy, 193  
 in transplant recipients, 159–162, 174
- Incident-dialysis patients, cardiovascular risk factors for peripheral arterial disease in, 304–313
- Infants  
 born to women with CKD, outcome of, 199–205  
 congenital anomalies, 202  
 developmental outcomes, 203  
 neonatal morbidity, 202  
 neonatal mortality, 200–201  
 teratogenic risks, 202–203
- Infections  
 management during pregnancy in kidney transplant recipients, 163–164, 172, 173–174
- Inflammation  
 ultrapure dialysate for home hemodialysis, 256–262
- Informatic profiling  
 improving cyclo prescriptions in peritoneal dialysis through, 263–268
- Informed consent  
 ethical issues in pregnancy in CKD, 206–207
- Insurance issues  
 Medicare  
 CKD care and reimbursement for preventive services (Special Article), 79–81  
 uninsured ESRD patients, 67–74  
 case report, 67–68  
 cost of dialysis, 69  
 health consequences for, 68–69  
 illegal immigrants, 71–72  
 Massachusetts health reform, 72–73  
 sources of compensation, 70–71  
 uncompensated care pool, 72  
 who are they, 69–70
- Internal filtration hemodiafiltration, 236–237
- Katrina. *See* Hurricane-prone areas.
- Kidney transplantation  
 counseling on pregnancy and contraception in women after, 128
- Kidney transplantation (*Continued*)  
 for ESRD patients in hurricane-prone areas, 103–104  
 pregnancy in women after  
 medical management of, 156–167  
 anemia, 164  
 caretakers of, 157  
 counseling, 156–157  
 hypertension during, 162–163  
 immunosuppressive medications during, 159–162  
 infections, 163–164  
 optimal timing of, 157  
 preeclampsia, 163  
 rejection, diagnosis and treatment of, 163  
 obstetric considerations in, 168–177  
 antepartum management, 174  
 effects of allograft on the pregnancy, 172–173  
 effects of pregnancy on the allograft, 169–172  
 intrapartum management, 174  
 postpartum management, 174–176  
 preconception counseling, 168–169  
 psychosocial issues in women with functioning, 361  
 quality of life after, 370–378  
 sexual function after, 123
- Kidney, bioartificial  
 in future of renal replacement therapy, 254
- Lactation. *See* Breast-feeding.
- Leflunomide  
 use during pregnancy in transplant recipients, 160
- Life expectancy  
 shortened, as ethical issue in pregnancy in CKD, 207–208
- Lipoprotein (a)  
 cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients, 304–313
- Lipoproteins  
 balance between low density and high density, role in vascular calcification in CKD, 60
- Living membranes  
 in future of renal replacement therapy, 254
- Lupus nephropathy  
 pregnancy outcomes in, 141–143
- Magnesium  
 as mimic/antagonist of calcium, role in vascular calcification in CKD, 59–60
- Malnutrition  
 nutrition assessment and hormonal influences on, in children with CKD, 215–223
- Marital issues  
 in women with ESRD, 360–361
- Marriage  
 social support and, in chronic disease, 339–340

- Massachusetts  
health reform in, and uninsured ESRD patients, 73–74
- Maternal outcome  
in pregnancy with CKD, 132–145
- Matrix Gla protein  
and Vitamin K, role in vascular calcification in CKD, 57–58
- Medicare  
CKD care and reimbursement for preventive services (Special Article), 79–81  
should ESRD program pay for daily dialysis, ethical analysis of, 290–296
- Medications  
use during pregnancy in women with CKD, 191–198  
antihypertensive drugs, 193–196  
changes in drug metabolism, 192–193  
immunosuppressive drugs, 193  
risk assessment for, 192
- Membranes  
in future of renal replacement therapy  
human nephron filter, 250–253  
living, 254  
silicone nanopore, 253–254
- Men with CKD  
sexual dysfunction in, 121  
hypogonadism in, 122–123
- Mental health  
and quality of life in CKD, 315–408  
after kidney transplantation, 370–378  
assessment of health-related quality of life in, 345–352  
depression in ESRD patients, 328–334  
dialysis discontinuation, 379–401  
editorial, 315  
health-related quality of life for children with, 364–369  
in women with ESRD, 358–364  
palliative care in ESRD, 402–408  
psychosocial assessment of chronic peritoneal dialysis patients, 353–357  
psychosocial factors (guest editorial), 316–318  
social support and, 335–344  
symptoms and their correlates, 319–327  
common distressing, and their treatment, 321–324  
in peritoneal dialysis and pre-ESRD patients, 324–323  
overall burden, severity, and importance of, 320–321
- Metabolism  
of bone, regulation in bone-mineral disorder in patients with CKD, 31–32  
of calcium in CKD, recommended intake and serum targets, 75–78  
of minerals, and mortality in patients with CKD, 13–21  
clinical outcomes related to, 13–19  
calcium-phosphorus product, 16–17  
parathyroid hormone, 17–19  
serum calcium concentration, 15–16
- Metabolism (*Continued*)  
serum phosphorus concentration, 13–15  
mechanism of link between, 19–20
- Microelectromechanical systems (MEMS)  
in future of renal replacement therapy, 254–255
- Microfluidics  
in future of renal replacement therapy, 2494–255
- Middleton hemodiafiltration, 238
- Mineral metabolism  
and mortality in patients with CKD, 13–21  
clinical outcomes related to, 13–17  
calcium-phosphorus product, 16–17  
parathyroid hormone, 17–19  
serum calcium concentration, 15–16  
serum phosphorus concentration, 13–15  
mechanism of link between, 19–20
- Mineral-bone disorder  
in chronic kidney disease (CKD-MBD), 1–66  
bone health in, 27–36  
diagnosis and screening, 27–32  
metabolic changes, 32–33  
morphologic presentations, 33–34  
editorial, 1  
guest editorial, 2  
management of, 44–53  
parathyroid hormone control, 47–51  
phosphorus control, 45–47  
mineral metabolism and mortality in, 13–21  
new paradigm, 3–12  
abnormalities of bone in, 6  
clinical manifestations of disturbances in, 4–6  
coexistence with other causes of bone and vascular disease, 10  
establishment of, 8  
renal osteodystrophy, 8–9  
vascular calcification, 6–8  
clinical assessment of, 37–43  
mechanisms of, 54–66  
vitamin D in, 22–26
- Minerals  
nutritional management in pregnancy in CKD, 213–214
- Monitoring  
during pregnancy in kidney transplant recipients, 164
- Morbidity  
neonatal, of infants born to women with CKD, 202
- Morphology  
of bone-mineral disorder in patients with CKD, 33–34
- Mortality  
in advanced CKD, stabilization of glomerular filtration rate and, 105–112  
mineral metabolism and, in patients with CKD, 13–21  
neonatal, of infants born to women with CKD, 200–201  
with hemodiafiltration, 241–242

- Mycophenolate mofetil  
use during pregnancy in transplant recipients, 160–162
- Nanoelectronics  
in future of renal replacement therapy, 254
- Nanopore membranes  
silicone, in future of renal replacement therapy, 253–254
- National Kidney Foundation (NKF)  
Clinical Meetings Abstracts (Spring 2007), 224–225
- Neonatal outcome  
of infants born to women with CKD, 199–205
- Nephron filter  
human, in future of renal replacement therapy, 250–253
- Nephropathy  
diabetic, pregnancy outcomes in, 140–141  
lupus, pregnancy outcomes in, 141–143
- Networks, ESRD  
development a central electronic health record for disaster-prone areas by, 104
- Neurocognitive issues  
in children with CKD, 365–366
- Nocturnal hemodialysis  
in children, 298–301  
thrice-weekly in-center program, 244–248
- Nutrition  
assessment of, and hormonal influences on body composition in children with CKD, 215–223  
anthropometric assessment, 219–220  
assessment of dietary intake, 216–218  
cachexia in, 220–221  
challenges in, 216  
laboratory data and, 218–219  
calcium, recommended intake and serum targets in CKD, 75–78  
in pregnancy with chronic kidney disease, 212–214  
energy and protein needs, 212–213  
other considerations, 214  
vitamins and minerals, 213–214
- NxStage system  
frequent hemodialysis in children with, 301–302
- Obstetric management  
of pregnancy in women after kidney transplantation, 168–177  
antepartum management, 174  
effects of allograft on the pregnancy, 172–173  
immunosuppressive drugs, 174  
infections, 173–174  
intrauterine growth restriction, 172–173  
preterm delivery, 172  
effects of pregnancy on the allograft, 169–172  
intrapartum management, 174  
postpartum management, 174–176  
preconception counseling, 168–169
- Online hemodiafiltration, 236–243  
fluid purity and biocompatibility in, 239–240
- Osteodystrophy. *See* Renal osteodystrophy.
- Outcomes, clinical  
maternal and fetal, of pregnancy with CKD, 132–145  
in diabetic nephropathy, 140–141  
in lupus nephropathy, 141–143  
in primary kidney disease, 135–139  
mineral metabolism and mortality in patients with CKD, 13–21  
calcium-phosphorus product and, 16–17  
parathyroid hormone and, 17–19  
serum calcium concentration and, 15–16  
serum phosphorus concentration and, 13–15  
outcome-driven nephrology social work, value of, 409–414  
three early intervention programs, evaluation of (abstract), 224
- Pain  
and quality of life in patients with CKD, 322–323  
prevalence in ESRD patients, 87–88
- Paired filtration hemodiafiltration, 237
- Palliative care  
in ESRD, 402–408  
communicating with patients and families, 403–406  
advance-care planning, 405–406  
end-of-life discussions, 404–405  
prognosis, 403–404  
dialysis discontinuation, 379–401  
hospice, 406
- Parathyroid hormone  
control in CKD–bone-mineral disorder, 47–51  
PTH assay methodology, 48–49  
treatment of elevated, 49–51  
active vitamin D sterols, 50–51  
calcimimetics, 51  
nutritional vitamin D, 49–50  
parathyroidectomy, 51  
role of calcium/vitamin D/parathyroid hormone/fibroblast growth factor 23 axis in vascular calcification, 56–57  
serum concentration in CKD, clinical outcome related to, 17–18
- Parathyroidectomy  
for elevated parathyroid hormone in CKD–bone-mineral disorder, 51
- Pediatric Quality of Life Inventory, 367–368
- Pediatrics  
frequent hemodialysis in children, 297–303  
daily intensive hemodiafiltration, 298  
dose monitoring, 302  
dose prescription, 301–302  
nocturnal, 298–300  
potential deficiency syndromes, 301  
with NxStage system, 301  
health-related quality of life for children with CKD, 363–369  
nutrition assessment and hormonal influences on body composition in children with CKD, 215–223  
anthropometric assessment, 219–220

- Pediatrics (*Continued*)  
 assessment of dietary intake, 216–218  
 cachexia in, 220–221  
 challenges in, 216  
 laboratory data and, 218–219
- Peripheral arterial disease  
 cardiovascular risk factors for, in incident-dialysis patients, 304–313
- Peritoneal dialysis  
 alternative regimens for, 263–289, *e27*, *e35*  
 assisted, 279–283  
 early start, *e27*  
 glucotoxicity in, solutions for, 269–278  
 home therapies, resurgence of, 284–289  
 improving cyclers prescriptions through informatic profiling, 263–268  
 quotidian hemodialysis and inflammation associated with CKD, *e35*  
 impact of focused techniques on peritonitis rates (abstract), 224  
 in pregnant patients, 152–153  
 increased utilization for ESRD patients in hurricane-prone areas, 103–104  
 psychosocial assessment of patients on chronic, 353–357  
 symptoms and quality of life in patients on, 324–325
- Peritonitis  
 impact of focused techniques on peritonitis rates in peritoneal dialysis (abstract), 224
- Phosphate binders  
 use in CKD–bone-mineral disorder, 46–47
- Phosphate/pyrophosphate balance  
 role in vascular calcification in CKD, 54–56
- Phosphorus  
 control in CKD–mineral-bone disorder, 45–47  
 diet, 45–46  
 improved dialytic clearance of, 47  
 phosphate binders, 46–47  
 serum concentration in CKD, clinical outcome related to, 13–15
- Physical examination  
 for new Medicare patients, and reimbursement for preventive services (Special Article), 79–81
- Placenta  
 pathophysiology of preeclampsia, 185
- Population profiling  
 improving cyclers prescriptions in peritoneal dialysis through, 263–264
- Pre-ESRD patients  
 symptoms and quality of life in, 324–325
- Preeclampsia  
 during pregnancy in kidney transplant recipients, 163, 171–172  
 during pregnancy in women with CKD, 184–188  
 clinical features and diagnosis, 184  
 pathophysiology of, 185–186  
 prevention and management, 184–185  
 treatment, 186–188
- Pregnancy  
 and chronic kidney disease, 113–214, 146–155  
 antihypertensive and immunosuppressive medications during, 191–198  
 contraceptive counseling for women with, 126–131  
 diagnosis of pregnancy in, 147  
 editorial, 113–114  
 ethical considerations in, 206–211  
 assisted reproductive technologies, 210  
 fetus as a patient, 208  
 informed consent and counseling, 206–207  
 resource allocation, 208–209  
 responsibilities for increased research and public debate, 210–211  
 rights, 208  
 shortened life expectancy, 207–208  
 frequency of, 146–147  
 guest editorial, 115  
 historical perspective, 116–118  
 hypertension in, 178–190  
 in kidney transplant recipients  
 contraceptive counseling for, 126–131  
 medical management of, 156–167  
 obstetric considerations in, 168–177  
 management of, 149–154  
 anemia, 149–150  
 diet, 153–154  
 hemodialysis, 151–152  
 hypertension, 150–151  
 peritoneal dialysis, 152–153  
 management of chronic dialysis in, 146–155  
 maternal and fetal outcomes, 132–145  
 nutritional management of, 212–214  
 energy and protein needs, 212–213  
 other considerations, 214  
 vitamins and minerals, 213–214  
 outcome of infants born to women with, 199–205  
 congenital anomalies, 202  
 developmental outcomes, 203  
 neonatal morbidity, 202  
 neonatal mortality, 200–201  
 teratogenic risks, 202–203  
 sexual function in CKD, 119–125
- Preventive care  
 and CKD, Medicare reimbursement for (Special Article), 79–81
- Profiling, informatic  
 improving cyclers prescriptions in peritoneal dialysis through, 263–268  
 adherence profiling, 266–267  
 flow profiling, 264–266  
 population profiling, 263–264
- Prognosis  
 in ESRD. communicating with patients and families, 405–406
- Progression  
 advanced CKD, stabilization of glomerular filtration rate in, 2-year follow-up of, 105–112
- Prolactin  
 for sexual dysfunction in CKD, 120–123

- Protein  
nutritional management in pregnancy in CKD, 212–213
- Proteinuria  
impact on pregnancy outcomes in primary maternal CKD, 139
- Pruritus  
prevalence in ESRD patients, 88
- Psychiatric disorders  
in women with ESRD, 359
- Psychosocial assessment  
of patients on chronic peritoneal dialysis, 353–357
- Psychosocial issues  
in women with ESRD, 358–363  
compliance, 360  
epidemiology, 358–359  
fertility and conception, 359–360  
marital issues, 360–361  
psychiatric disorders, 359  
with a functioning kidney transplant, 361
- Public policy  
uninsured ESRD patients, 67–74  
case report, 67–68  
cost of dialysis, 69  
health consequences for, 68–69  
illegal immigrants, 71–72  
Massachusetts health reform, 72–73  
sources of compensation, 70–71  
uncompensated care pool, 72  
who are they, 69–70
- Push-pull hemodiafiltration, 238–239
- Pyrophosphate  
phosphate/pyrophosphate balance, role in vascular calcification in CKD, 54–56
- Quality of life, health-related  
after kidney transplantation, 370–378  
and psychosocial issues in women with ESRD, 358–363  
compliance, 360  
epidemiology, 358–359  
fertility and conception, 359–360  
marital issues, 360–361  
psychiatric disorders, 359  
with a functioning kidney transplant, 361  
assessment of among CKD patients, 345–352  
barriers to, 349–350  
clinical application of, 349  
evolution of treatment goals and, 347–348  
experience in clinical practice with, 350  
improving care via, 350–351  
measurement of, 346–347  
properties of a useful tool for, 348  
sources of information on, 348  
*versus* quality of life, 346  
outcome-driven nephrology social work, value of, 409–414  
social support for CKD patients and, 335–344  
definition, 335–336  
interaction with chronic disease, 336–340  
access to health care and, 336–337
- Quality of life, health-related (*Continued*)  
compliance and, 338–340  
depression and, 337–338  
immune function and, 340  
marriage and, 339–340  
survival and, 340–341  
symptoms and their correlates in CKD, 319–327  
common distressing, and their treatment, 321–324  
pain, 322–323  
sexual dysfunction, 323–324  
sleep disturbance, 324  
in peritoneal dialysis and pre-ESRD patients, 324–325  
overall burden, severity, and importance of, 320–321  
with hemodiafiltration, 241
- Rejection, transplant  
during pregnancy, diagnosis and treatment of, 163, 170
- Renal osteodystrophy, 8–9
- Renal replacement therapy  
future of, 249–255  
human nephron filter, 250–253  
living membranes and bioartificial kidney, 254  
nanoelectronics, 254  
silicone nanopore membranes, 253–254  
stem cells, 254
- Reproductive technologies  
assisted, ethical issues in pregnancy in CKD, 210
- Research  
responsibility for increased, as ethical issue in pregnancy in CKD, 210–211
- Resource allocation  
ethical issues in pregnancy in CKD, 208–209
- Restless legs syndrome  
prevalence in ESRD patients, 88
- Rights, patient  
ethical issue in pregnancy in CKD, 208
- Risk factors  
cardiovascular, for peripheral arterial disease in incident-dialysis patients, 304–313
- Roentgenography  
in assessment of vascular calcification in CKD, 37–38
- Sexual dysfunction  
and quality of life in patients with CKD, 323–324
- Sexual function  
in CKD, 119–125  
after kidney transplantation, 123  
clinical manifestations  
in men, 120  
in women, 120  
erythropoietin and, 121  
treatment of sexual dysfunction  
in men, hypogonadism and, 122–123  
in women, 120–121
- Sildenafil citrate  
for hypogonadism in men with CKD, 123

- Silicone nanopore membranes  
in future of renal replacement therapy, 253–254
- Sirolimus  
use during pregnancy in transplant recipients, 160–162
- Sleep disturbance  
and quality of life in patients with CKD, 324  
prevalence in ESRD patients, 88–91
- Social support  
for CKD patients, 335–344  
definition, 335–336  
interaction with chronic disease, 336–340  
access to health care and, 336–337  
compliance and, 338–340  
depression and, 337–338  
immune function and, 340  
marriage and, 339–340  
survival and, 340–341
- Social work  
outcome-driven, value of, 409–414
- Stem cells  
in future of renal replacement therapy, 254
- Support. *See* Social support.
- Survival  
social support and, in chronic disease, 340–341
- Symptoms  
and their correlates in CKD, 319–327  
common distressing, and their treatment, 321–324  
pain, 322–323  
sexual dysfunction, 323–324  
sleep disturbance, 324  
in peritoneal dialysis and pre-ESRD patients, 324–323  
overall burden, severity, and importance of, 320–321  
prevalence in ESRD patients, 82–99
- Tacrolimus  
use during pregnancy in transplant recipients, 160
- Teratogenic risk  
to infants born to women with CKD, 202–203
- Testosterone replacement therapy  
for hypogonadism in men with CKD, 122
- Time management  
outcome-driven nephrology social work, value of, 409–414
- Toxoplasmosis  
infections during pregnancy in kidney transplant recipients, 173
- Transplantation. *See* Kidney transplantation.
- Ultrapure dialysate  
for home hemodialysis, 256–262  
benefits of, 258–259  
microbiology of water and dialysate, 257–258  
preparation of, 259–261
- Ultrasonography  
in assessment of vascular calcification in CKD, 38–39
- Uncompensated-care pool, 72
- Uninsured patients  
with ESRD, 67–74  
case report, 67–68  
cost of dialysis, 69  
health consequences for, 68–69  
illegal immigrants, 71–72  
Massachusetts health reform, 72–73  
sources of compensation, 70–71  
uncompensated care pool, 72  
who are they, 69–70
- Urinary tract infections  
management during pregnancy in kidney transplant recipients, 172
- Vascular calcification  
in CKD, 6–8  
clinical assessment of, 37–43  
arterial complications, 41  
computed tomography, 39–41  
echocardiography, 39  
roentgenography, 37–38  
ultrasonography, 38–39  
mechanisms of, 54–66  
 $\alpha 2$  Heremans-Schmid glycoprotein (fetuin A, Absg), 58–59  
BMP-7, 58  
bone morphogenetic protein-2/Msx2/Wnt pathway, 57  
calcium/vitamin D/parathyroid hormone/fibroblast growth factor 23 axis, 56–57  
low-density lipoprotein/high-density lipoprotein balance, 60  
magnesium, 59–60  
matrix G1a protein/vitamin K duo, 57–58  
phosphate/pyrophosphate balance, 54–56
- Vascular disease  
coexistence of mineral-bone disorder with other causes of, 10
- Vitamins  
nutritional management in pregnancy in CKD, 213–214  
vitamin D  
for elevated parathyroid hormone in CKD–bone-mineral disorder, 49–51  
active sterols, 50  
nutritional, 49–50  
in patients with CKD, 23–26  
role of calcium/vitamin D/parathyroid hormone/fibroblast growth factor 23 axis in vascular calcification, 56–57  
vitamin K  
and matrix G1a protein, role in vascular calcification in CKD, 57–58
- Water  
microbiology of, in ultrapure dialysate for home hemodialysis, 256–262
- Women  
with CKD  
pregnancy in. *See* Pregnancy.  
sexual dysfunction in, 120–121

Women (*Continued*)

- with ESRD, psychosocial and quality of life issues in, 358–363
- compliance, 360
- epidemiology, 358–359

Women (*Continued*)

- fertility and conception, 359–360
- marital issues, 360–361
- psychiatric disorders, 359
- with a functioning kidney transplant, 361